URGN - UroGen Pharma Ltd Stock Price, Fair Value and News

14.16USD+0.34 (+2.46%)Market Closed

Market Summary

USD14.16+0.34

Market Closed

2.46%

URGN Alerts

1 major insider sales recently.

URGN Stock Price

View Fullscreen

URGN RSI Chart

URGN Valuation

Market Cap

483.2M

Price/Earnings (Trailing)

-4.73

Price/Sales (Trailing)

5.84

EV/EBITDA

-4.99

Price/Free Cashflow

-6.31

URGN Price/Sales (Trailing)

URGN Profitability

Operating Margin

88.68%

EBT Margin

-118.87%

Return on Equity

156.79%

Return on Assets

-57.34%

Free Cashflow Yield

-15.85%

URGN Fundamentals

URGN Revenue

Revenue (TTM)

82.7M

Rev. Growth (Yr)

30.06%

Rev. Growth (Qtr)

12.84%

URGN Earnings

Earnings (TTM)

-102.2M

Earnings Growth (Yr)

9.88%

Earnings Growth (Qtr)

-18.91%

Breaking Down URGN Revenue

Last 7 days

3.1%

Last 30 days

-5.3%

Last 90 days

-11.9%

Trailing 12 Months

13.6%

How does URGN drawdown profile look like?

URGN Financial Health

Current Ratio

5.42

Debt/Equity

-1.51

Debt/Cashflow

-0.77

URGN Investor Care

Shares Dilution (1Y)

33.68%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	68.0M	72.5M	77.3M	82.7M
2022	54.1M	57.7M	62.4M	64.4M
2021	19.3M	31.9M	39.8M	48.0M
2020	7.2M	8.8M	10.3M	11.8M
2019	0	2.7M	4.2M	5.7M
2018	8.6M	9.0M	1.5M	1.1M
2017	15.2M	12.8M	10.5M	8.2M
2016	0	0	0	17.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of UroGen Pharma Ltd

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 18, 2024	schoenberg mark	sold	-168,600	14.05	-12,000	chief medical officer
Feb 01, 2024	schoenberg mark	sold	-59,790	15.78	-3,789	chief medical officer
Feb 01, 2024	smith jason drew	sold	-78,789	15.78	-4,993	general counsel
Jan 31, 2024	schoenberg mark	acquired	-	-	6,666	chief medical officer
Jan 31, 2024	kim dong	acquired	-	-	3,333	chief financial officer
Jan 31, 2024	smith jason drew	acquired	-	-	10,000	general counsel
Jan 31, 2024	schoenberg mark	sold	-59,638	15.74	-3,789	chief medical officer
Jan 31, 2024	smith jason drew	sold	-78,589	15.74	-4,993	general counsel
Aug 31, 2023	smith jason drew	sold	-68,438	18.01	-3,800	general counsel

Which funds bought or sold URGN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Lindbrook Capital, LLC	added	158	1,470	2,400	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-2.69	-28,275	1,023,280	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	reduced	-57.83	-57,000	42,000	-%
Apr 24, 2024	AlphaCentric Advisors LLC	reduced	-7.16	-166,530	2,158,470	1.30%
Apr 23, 2024	AMALGAMATED BANK	reduced	-70.88	-35,000	14,000	-%
Apr 23, 2024	RICE HALL JAMES & ASSOCIATES, LLC	added	0.74	7,710	1,056,090	0.06%
Apr 23, 2024	BENDER ROBERT & ASSOCIATES	unchanged	-	-	520,515	0.12%
Apr 22, 2024	SHIKIAR ASSET MANAGEMENT INC	unchanged	-	-	499,000	0.15%
Apr 22, 2024	MetLife Investment Management, LLC	added	40.59	73,644	219,390	-%
Apr 18, 2024	ARK Investment Management LLC	reduced	-9.41	-227,940	2,194,940	0.01%

Are Funds Buying or Selling URGN?

Are funds buying URGN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own URGN

No. of Funds

URGN Alerts

1 major insider sales recently.

Unveiling UroGen Pharma Ltd's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 22, 2024	arkin moshe	4.44%	1,369,315	SC 13D/A
Feb 14, 2024	rtw investments, lp	5.6%	1,726,808	SC 13G
Feb 14, 2024	menora mivtachim holdings ltd.	7.46%	2,303,031	SC 13G/A
Feb 14, 2024	ra capital management, l.p.	9.99%	3,083,558	SC 13G/A
Feb 14, 2024	great point partners llc	8.49%	2,620,545	SC 13G/A
Feb 13, 2024	stonepine capital management, llc	0%	0	SC 13G/A
Feb 02, 2024	blackrock inc.	5.6%	1,719,304	SC 13G
Dec 29, 2023	ra capital management, l.p.	9.99%	3,083,550	SC 13G
Sep 15, 2023	great point partners llc	8.51%	2,620,545	SC 13G
Aug 04, 2023	monograph capital holdings advisors, llc	5.1%	1,572,327	SC 13D

Recent SEC filings of UroGen Pharma Ltd

View All Filings

Date Filed	Form Type	Document
Mar 20, 2024	4	Insider Trading
Mar 18, 2024	144	Notice of Insider Sale Intent
Mar 14, 2024	10-K	Annual Report
Mar 14, 2024	8-K	Current Report
Mar 04, 2024	8-K	Current Report
Mar 01, 2024	8-K	Current Report
Feb 22, 2024	SC 13D/A	13D - Major Acquisition
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to UroGen Pharma Ltd)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

UroGen Pharma Ltd News

Latest updates

UroGen Pharma Ltd Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4	2018Q3
Revenue	12.8%	23,530,000	20,852,000	21,139,000	17,192,000	18,092,000	16,097,000	16,604,000	13,564,000	16,174,000	11,351,000	13,032,000	7,485,000	7,966,000	3,461,000	372,000	297,600	223,200	148,800	74,400	-	283,000
Cost Of Revenue	-3.4%	2,286,000	2,367,000	2,443,000	2,265,000	2,263,000	2,020,000	1,846,000	1,525,000	1,589,000	1,244,000	1,427,000	897,000	652,000	309,000	48,000	-	-	-	-	-	1,055,000
Gross Profit	14.9%	21,244,000	18,485,000	18,696,000	14,927,000	15,829,000	14,077,000	14,758,000	12,039,000	14,585,000	10,107,000	11,605,000	6,588,000	7,314,000	3,152,000	324,000	-	-	-	18,000	-	-772,000
S&GA Expenses	12.9%	24,551,000	21,755,000	22,494,000	24,474,000	21,634,000	19,071,000	20,833,000	21,300,000	21,418,000	21,624,000	22,304,000	22,189,000	22,163,000	22,065,000	24,018,000	21,973,000	19,745,000	13,972,000	13,775,000	12,552,000	10,743,000
R&D Expenses	10.5%	11,302,000	10,230,000	11,584,000	12,498,000	14,477,000	13,093,000	12,640,000	12,696,000	13,082,000	11,923,000	12,124,000	10,513,000	12,405,000	10,211,000	8,106,000	16,588,000	20,094,000	9,481,000	9,996,000	11,465,000	9,574,000
EBITDA Margin	11.9%	-1.18	-1.34	-1.47	-1.61	-1.66	-1.70	-1.93	-2.04	-2.26	-2.72	-3.36	-5.85	-10.57	-	-	-	-	-	-	-	-
Income Taxes	42922.2%	3,854,000	-9,000	54,000	21,000	689,000	709,000	32,000	325,000	1,137,000	-	312,000	-	3,374,000	-	-	-	-	-	-	-	-
Earnings Before Taxes	-1.3%	-22,162,000	-21,888,000	-24,082,000	-30,192,000	-28,180,000	-25,122,000	-26,659,000	-28,067,000	-27,315,000	-30,211,000	-25,910,000	-25,935,000	-27,152,000	-28,816,000	-31,349,000	-	-	-	-	-	-
EBT Margin	12.0%	-1.19	-1.35	-1.48	-1.62	-1.68	-1.72	-1.95	-2.06	-2.28	-2.74	-3.38	-5.87	-10.60	-	-	-	-	-	-	-	-
Net Income	-18.9%	-26,016,000	-21,879,000	-24,136,000	-30,213,000	-28,869,000	-25,831,000	-26,691,000	-28,392,000	-28,452,000	-30,211,000	-26,222,000	-25,935,000	-30,526,000	-28,816,000	-31,349,000	-37,793,000	-38,973,000	-22,252,000	-22,477,000	-23,716,000	-20,533,000
Net Income Margin	9.1%	-1.24	-1.36	-1.50	-1.64	-1.71	-1.75	-1.97	-2.09	-2.31	-2.83	-3.49	-6.05	-10.89	-	-	-	-	-	-	-	-
Free Cashflow	25.0%	-13,052,000	-17,399,000	-20,289,000	-25,830,000	-21,765,000	-17,765,000	-24,262,000	-24,021,000	-20,272,000	-18,670,000	-19,014,000	-27,688,000	-21,414,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-7.9%	178	194	95.00	113	136	128	146	166	120	135	154	97.00	122	140	161	167	202	227	239	252	104
Current Assets	-7.1%	169	182	81.00	96.00	129	122	140	161	114	125	140	93.00	116	129	130	122	149	160	191	248	102
Cash Equivalents	-20.4%	95.00	119	20.00	37.00	55.00	29.00	81.00	105	44.00	55.00	63.00	40.00	53.00	25.00	36.00	26.00	50.00	66.00	90.00	247	101
Inventory	13.4%	6.00	5.00	5.00	5.00	4.00	5.00	5.00	5.00	5.00	4.00	3.00	3.00	2.00	1.00	1.00	-	-	-	-	-	-
Net PPE	-16.3%	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	3.4%	244	236	234	230	225	192	187	183	111	103	97.00	21.00	26.00	19.00	18.00	16.00	22.00	16.00	14.00	12.00	13.00
Current Liabilities	21.0%	31.00	26.00	27.00	25.00	24.00	19.00	18.00	19.00	22.00	20.00	19.00	17.00	21.00	18.00	16.00	14.00	19.00	14.00	12.00	10.00	13.00
Long Term Debt	0.0%	99.00	99.00	98.00	98.00	98.00	72.00	71.00	71.00	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	0.0%	99.00	99.00	98.00	98.00	98.00	72.00	71.00	71.00	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-Infinity%	-65.21	-	-	-	-89.36	-	-	-	8.00	32.00	56.00	76.00	96.00	121	143	150	180	211	225	240	90.00
Retained Earnings	-4.0%	-679	-653	-631	-607	-577	-548	-522	-495	-467	-438	-408	-382	-356	-325	-297	-265	-228	-189	-166	-144	-122
Additional Paid-In Capital	0.4%	614	611	493	491	488	485	481	479	476	470	465	459	453	446	439	416	408	400	391	384	213
Shares Outstanding	5.2%	33.00	31.00	24.00	23.00	23.00	23.00	23.00	23.00	22.00	22.00	22.00	22.00	22.00	-	-	-	-	-	-	-	-
Float	-	-	-	190	-	-	-	145	-	-	-	251	-	-	-	525	-	-	-	695	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	24.9%	-12,996	-17,299	-20,274	-25,807	-21,752	-17,612	-24,199	-23,996	-20,070	-18,476	-18,945	-27,401	-21,242	-25,080	-23,929	-35,635	-26,000	-12,528	-14,555	-17,934	-10,284
Share Based Compensation	17.4%	2,611	2,224	2,222	2,286	2,368	2,440	2,823	2,949	5,357	5,515	6,046	6,195	6,526	6,763	7,119	7,617	8,065	7,243	7,212	7,447	8,877
Cashflow From Investing	-2928.9%	-11,344	401	3,720	6,270	23,108	-35,493	-151	13,596	9,125	10,660	-30,740	15,024	49,465	13,234	17,514	13,025	9,296	-12,659	-142,186	-44.00	-26.00
Cashflow From Financing	-100.0%	40.00	116,077	143	671	25,368	1,101	-77.00	70,742	-32.00	-168	72,515	4.00	78.00	61.00	16,298	90.00	245	1,126	373	163,506	2,200

URGN Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue	$ 82,713	$ 64,357
Cost of revenue	9,361	7,654
Gross profit	73,352	56,703
Operating expenses:
Research and development expenses	45,614	52,906
Selling, general and administrative expenses	93,274	82,838
Operating loss	(65,536)	(79,041)
Financing on prepaid forward obligation	(21,552)	(21,559)
Interest expense on long-term debt	(14,715)	(8,438)
Interest and other income, net	3,479	1,010
Loss before income taxes	(98,324)	(108,028)
Income tax expense	(3,920)	(1,755)
Net Loss	(102,244)	(109,783)
Statements of Comprehensive Loss
Net loss	(102,244)	(109,783)
Other comprehensive income (loss)
Unrealized gain (loss) on investments	119	(82)
Comprehensive Loss	$ (102,125)	$ (109,865)
Net loss per ordinary share - basic and diluted (in dollars per share)	$ (3.55)	$ (4.81)
Weighted average number of shares outstanding used in computation of basic and diluted loss per ordinary share (in shares)	28,834,303	22,806,812

URGN Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 95,002	$ 55,408
Marketable securities	41,966	44,556
Restricted cash	821	813
Accounts receivable	15,443	12,704
Inventories	5,673	4,325
Prepaid expenses and other current assets	10,281	11,101
Total current assets	169,186	128,907
Non-current assets:
Property and equipment, net	689	1,297
Restricted deposit	225	223
Right-of-use assets	1,671	2,452
Marketable securities	4,502	0
Other non-current assets	2,038	2,740
Total Assets	178,311	135,619
Current liabilities:
Accounts payable and accrued expenses	16,538	12,383
Employee related accrued expenses	10,814	8,257
Other current liabilities	3,860	3,276
Total current liabilities:	31,212	23,916
Non-current liabilities:
Prepaid forward obligation	109,722	98,923
Long-term debt	98,551	97,537
Long-term lease liabilities	844	1,586
Uncertain tax positions liability	3,194	3,018
Total Liabilities	243,523	224,980
Commitments and Contingencies (Note 19)
Shareholders' Deficit:
Ordinary shares, NIS 0.01 par value; 100,000,000 shares authorized at December 31, 2023 and 2022; 32,490,119 and 23,129,953 shares issued and outstanding as of December 31, 2023 and 2022, respectively	89	63
Additional paid-in capital	614,035	487,787
Accumulated deficit	(679,348)	(577,104)
Accumulated other comprehensive income (loss)	12	(107)
Total Shareholders' Deficit	(65,212)	(89,361)
Total Liabilities and Shareholders' Deficit	$ 178,311	$ 135,619

About UroGen Pharma Ltd

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for NMIBC. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

CEO	Ms. Elizabeth A. Barrett
WEBSITE	urogen.com
INDUSTRY	Biotechnology
EMPLOYEES	193

UroGen Pharma Ltd Frequently Asked Questions

What is the ticker symbol for UroGen Pharma Ltd? What does URGN stand for in stocks?

URGN is the stock ticker symbol of UroGen Pharma Ltd. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of UroGen Pharma Ltd (URGN)?

As of Fri Apr 26 2024, market cap of UroGen Pharma Ltd is 483.17 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of URGN stock?

You can check URGN's fair value in chart for subscribers.

What is the fair value of URGN stock?

You can check URGN's fair value in chart for subscribers. The fair value of UroGen Pharma Ltd is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of UroGen Pharma Ltd is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for URGN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is UroGen Pharma Ltd a good stock to buy?

The fair value guage provides a quick view whether URGN is over valued or under valued. Whether UroGen Pharma Ltd is cheap or expensive depends on the assumptions which impact UroGen Pharma Ltd's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for URGN.

What is UroGen Pharma Ltd's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, URGN's PE ratio (Price to Earnings) is -4.73 and Price to Sales (PS) ratio is 5.84. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. URGN PE ratio will change depending on the future growth rate expectations of investors.